Nov 5- Keryx Biopharmaceuticals Inc's kidney drug proved effective in treating chronic kidney disease patients not on dialysis, sending the company's shares to a seven-year high on hopes the drug could achieve blockbuster status. "This is great news that opens up the pre-dialysis market for the company," Maxim Group analyst Jason Kolbert told Reuters.
Nov 5- Keryx Biopharmaceuticals Inc said its sole drug in development, Zerenex, proved to be effective in treating patients with chronic kidney disease who were not on dialysis. Keryx shares jumped 20 percent after the company said Zerenex met the main goal of a mid-stage trial.
Nov 5- Keryx Biopharmaceuticals Inc said its kidney drug met the main goals of a mid-stage study in patients with chronic kidney disease who were not on dialysis. Shares of the company rose about 16 percent to $12.84 in premarket trading.
Sometimes Jim Cramer needs to do homework before he can make a decision on a stock. Following is his research.
"Mad Money" host Jim Cramer makes calls on viewer's favorite stocks: Southern Copper, Oneok and more.
Oct 10- Keryx Biopharmaceuticals Inc:. *Ladenburg raises Keryx Biopharmaceuticals price target to $5 from. Reuters Station users, click. 1568.
Drug firms have already agreed to significant price cuts in hope that this would be offset by the influx of customers from the individual mandate being passed, reports CNBC's Seema Mody.
The bulls were all over Keryx Biopharmaceuticals and AEterna Zentaris Monday amid optimism about their Perifosine drug.
A check on why the market has not realized the potential for Aeterna Zantaris and Keryx Biopharmaceuticals, and the Fast Money traders take a look at the stocks trending on Twitter.
Hedge funds peeled back the curtain this week to reveal a bit about what biotech stocks they were buying and selling during the second quarter.
The Lightning Round is extended in this CNBC.com exclusive feature.
Cramer makes the call on viewers' favorite stocks.